Quest Diagnostics (DGX)
(Delayed Data from NYSE)
$146.01 USD
-0.83 (-0.57%)
Updated Jul 19, 2024 04:00 PM ET
2-Buy of 5 2
B Value D Growth A Momentum B VGM
Price, Consensus and EPS Surprise
DGX 146.01 -0.83(-0.57%)
Will DGX be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for DGX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for DGX
Patterson (PDCO) Expands AI Solutions in Canada via Alliance
Edwards Lifesciences (EW) Buys Innovalve to Boost TMVR Solutions
DGX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio
Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio
AMN Healthcare (AMN) Unveils ShiftWise Flex Manager Hub App
Other News for DGX
Quest Diagnostics Market Position and Earnings Potential: Analyst Pito Chickering’s Outlook amidst Inflationary Challenges and Growth Strategies
Tesla, Alphabet, GM, Ford Lead Earnings Parade This Week As Market Struggles To Sustain The Summer Rally
Labcorp, Quest among health firms to cite impact from CrowdStrike issue
Lisata to use Haystack technology to evaluate pancreatic cancer asset certepetide
Fiduciary Management Q2 2024 Investment Strategy Outlook